Table 1. Demographics, GBA and LRRK2 mutation status in PD cases and controls.
| PD cases (n=548) | Controls (n=272) | p-value | |
|---|---|---|---|
| Mean age in years, (SD) | 66.0 (10.5) | 65.3 (9.5) | 0.339 |
| Percent male, (n) | 64.4% (353) | 34.9% (95) | <0.001 |
| Percent with at least one Ashkenazi Jewish grandparent, (n) | 43.8% (240) | 39.9% (107) | 0.521 |
| Percent with family history of PD in first-degree relative, (n) | 17.5% (96) | 4.8% (13) | <0.001 |
| Carriers of LRRK2 p.G2019S | 7.3% (40) | 0.7% (2) | <0.001 |
| Carriers of any GBA variants1 | 16.6% (91) | 6.6% (18) | <0.001 |
| Education in years, (SD) | 16.6 (2.9) | 16.7 (2.7) | 0.691 |
| UPDRS- part III, (SD) | 17.9 (10.6) | 1.0 (1.8) | <0.001 |
| MoCA, (SD) | 25.3 (3.7) | 27.0 (2.2) | <0.001 |
| Mean PD age-at-onset, (SD) | 59.2 (11.6) | ||
| Levodopa equivalent daily dose in mg, (SD) | 535 (461) |
1
Including heterozygotes, homozygotes and compound heterozygotes of GBA mutations and variants11
UPDRS: Unified Parkinson's Disease Rating Scale
MoCA: Montreal Cognitive Assessment